Loading
Deep sequencing of 26 separate metastases from four patients found the same driver mutations in every one, so a biopsy of any single site should represent the whole disease for targeted therapy.
Sixty-fold whole-genome sequencing of 26 metastases from four patients with pancreatic cancer showed identical mutations in known driver genes in every metastatic lesion for each patient. Passenger mutations accounted for all intratumoural heterogeneity, and even among those the genetic similarity of founding cells was higher than expected for two randomly chosen normal cells.
Encouraging for targeted therapy: unlike some cancers, the drivers do not differ between deposits, so one biopsy is enough to choose a RAS or repair-directed drug.
Shares Bert Vogelstein, Clonal evolution & minimal residual disease, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Whole-exome & whole-genome sequencing.
Shares Clonal evolution & minimal residual disease, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Whole-exome & whole-genome sequencing, Memorial Sloan Kettering Cancer Center.
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Pancreatic ductal adenocarcinoma.
Shares Clonal evolution & minimal residual disease, Memorial Sloan Kettering Cancer Center, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Clonal evolution & minimal residual disease, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Whole-exome & whole-genome sequencing, Pancreatic ductal adenocarcinoma.
Shares Nature Genetics, Whole-exome & whole-genome sequencing.
Shares Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.
Shares Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.